Cargando…
New developments in systemic lupus erythematosus
In this review, the results of recent and ongoing clinical trials in patients with SLE are discussed. After many unsuccessful trials in the past decade, belimumab was the first biologic specifically designed for SLE that met its primary end point. At the same time, studies on the pathophysiology of...
Autores principales: | Tsang-A-Sjoe, Michel W. P., Bultink, Irene E. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709564/ https://www.ncbi.nlm.nih.gov/pubmed/34951924 http://dx.doi.org/10.1093/rheumatology/keab498 |
Ejemplares similares
-
Treatment targets in SLE: remission and low disease activity state
por: Golder, Vera, et al.
Publicado: (2020) -
Systemic lupus erythematosus and fractures
por: Bultink, Irene E M, et al.
Publicado: (2015) -
Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus
por: Bultink, Irene E. M.
Publicado: (2017) -
Dilemma of immunosuppression and infection risk in systemic lupus erythematosus
por: He, Jing, et al.
Publicado: (2023) -
Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs
por: Ruiz-Irastorza, Guillermo, et al.
Publicado: (2020)